Depression is, by every biological measure, accelerated aging applied to the brain. Recurrent and chronic depressive illness is associated with shortened leukocyte telomeres, accelerated epigenetic age (as measured by Horvath and similar clocks), reduced hippocampal volume, white matter hyperintensities beyond age-matched controls, inflammatory load, and elevated all-cause mortality independent of suicide. The cognitive cost is measurable — patients with multiple lifetime depressive episodes show greater age-related cognitive decline and elevated dementia risk in long-follow-up cohorts. The longevity-psychiatry frame treats this directly: every depressive episode is a longevity event, every untreated or undertreated episode adds cumulative damage, and aggressive evidence-based treatment is one of the most powerful neuroprotective interventions available.
Telomere length and epigenetic aging are now well-replicated biomarkers in depression. Patients with major depressive disorder, particularly those with multiple episodes or chronic illness, show telomere shortening on the order of 3–5 years of biological age relative to non-depressed controls in meta-analyses. Epigenetic clocks (DNAm GrimAge, PhenoAge) show similar acceleration, with the effect partially attenuated by remission. These are not just markers; they are mechanistic — the same inflammatory, mitochondrial, and HPA pathways that drive depression also drive cellular aging, and the overlap is substantial.
Hippocampal volume loss in recurrent depression is robust across imaging studies. The Sheline meta-analyses and subsequent work have shown that patients with recurrent depression have hippocampal volumes 4–10% smaller than matched controls, with the magnitude correlated with cumulative duration of untreated illness. The mechanism is multi-pathway: chronic glucocorticoid exposure produces dendritic atrophy in CA3 pyramidal neurons; inflammation suppresses neurogenesis in the dentate gyrus; BDNF reduction limits plasticity. The hippocampus is the structural substrate of memory and the central node of cognitive aging; its volume in depression is a quantitative measure of the longevity cost of the illness.
The kindling phenomenon and recurrence biology amplify the cost. Each depressive episode appears to lower the threshold for the next — Post and others have characterized this as kindling, with later episodes occurring with less precipitating stress and with greater resistance to treatment. The neurobiological corollary is that untreated or partially treated depression produces a self-reinforcing trajectory: more episodes, more brain aging, more cognitive cost, more treatment resistance. The clinical implication is uncomfortable but accurate: the patient on inadequate treatment is accumulating biological damage that may be largely preventable.
The dementia connection is now well-established. Late-life depression is both a risk factor for and an early sign of dementia; depression in midlife elevates dementia risk in long-follow-up cohorts with hazard ratios of 1.5–2.0; recurrent depression across the lifespan compounds risk. The Lancet Commission lists depression as one of the modifiable factors for dementia prevention, with a population-attributable fraction in the 3–4% range. The mechanism is the same as the accelerated-aging biology — sustained inflammatory, HPA, and vascular pathology — and the clinical move is to treat depression as a cognitive risk factor that demands durable remission, not just symptom reduction.
The therapeutic implication is to treat aggressively for remission, not response. Partial response is biologically inadequate — residual symptoms continue to produce the same accelerated-aging biology that the index episode produced. The longevity-psychiatry frame supports earlier escalation, broader workup, and more attention to preventive maintenance than conventional depression treatment paradigms. The patient who has been on suboptimal treatment for years is accumulating cost; the patient achieved durable remission with aggressive layered treatment is having that trajectory bent toward a substantially better cognitive future. Depression is not just a mood disorder. It is a longevity disorder with measurable biological consequences, and the work of treating it well is some of the most important neuroprotection available in psychiatry.